See more : Lear Corporation (LEA) Income Statement Analysis – Financial Results
Complete financial analysis of Amarin Corporation plc (AMRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amarin Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- GoldCoin Health Foods Limited (GOLDCOINHF.BO) Income Statement Analysis – Financial Results
- Itiquira Acquisition Corp. (ITQRW) Income Statement Analysis – Financial Results
- Magazine Luiza S.A. (MGLUY) Income Statement Analysis – Financial Results
- Covalon Technologies Ltd. (COV.V) Income Statement Analysis – Financial Results
- Mainichi Comnet Co., Ltd. (8908.T) Income Statement Analysis – Financial Results
Amarin Corporation plc (AMRN)
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 306.91M | 369.19M | 583.19M | 614.06M | 429.76M | 229.21M | 181.10M | 130.08M | 81.76M | 54.20M | 26.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 1.02M | 7.37M | 65.51M | 53.77M | 17.55M | 11.22M | 19.00M | 24.30M | 21.50M | 29.10M | 18.70M | 14.70M |
| Cost of Revenue | 141.37M | 126.71M | 121.33M | 131.44M | 96.02M | 54.54M | 44.95M | 34.36M | 27.88M | 20.49M | 11.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 107.00K | 11.91M | 30.13M | 21.46M | 5.22M | 2.98M | 3.70M | 2.80M | 4.00M | 4.90M | 0.00 | 3.10M |
| Gross Profit | 165.54M | 242.48M | 461.86M | 482.62M | 333.74M | 174.67M | 136.15M | 95.72M | 53.88M | 33.72M | 14.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 910.00K | -4.55M | 35.38M | 32.32M | 12.33M | 8.24M | 15.30M | 21.50M | 17.50M | 24.20M | 18.70M | 11.60M |
| Gross Profit Ratio | 53.94% | 65.68% | 79.20% | 78.59% | 77.66% | 76.20% | 75.18% | 73.58% | 65.90% | 62.21% | 54.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 89.48% | -61.74% | 54.01% | 60.10% | 70.25% | 73.47% | 80.53% | 88.48% | 81.40% | 83.16% | 100.00% | 78.91% |
| Research & Development | 22.22M | 30.41M | 29.31M | 38.96M | 34.39M | 55.90M | 47.16M | 49.98M | 51.06M | 50.33M | 72.75M | 58.96M | 21.60M | 28.01M | 17.84M | 12.95M | 12.11M | 17.19M | 8.31M | 3.48M | 5.44M | 6.22M | 4.14M | 5.75M | 7.44M | 19.80M | 19.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.61M | 118.80M | 141.86M | 112.66M | 323.62M | 180.18M | 112.04M | 93.40M | 93.07M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 111.33M | 185.61M | 266.47M | 350.65M | 0.00 | 46.82M | 22.51M | 17.97M | 7.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 199.94M | 304.42M | 408.33M | 463.31M | 323.62M | 227.00M | 134.55M | 111.37M | 101.04M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 15.25M | 15.23M | 19.46M | 13.27M | 9.77M | 9.03M | 30.89M | 23.66M | 33.26M | 9.14M | 5.30M | 9.70M | 7.30M | 34.60M | 18.60M | 0.00 | 9.90M |
| Other Expenses | 10.97M | -740.00K | -302.00K | 104.00K | -75.00K | -326.00K | 74.00K | -482.00K | -228.00K | 3.73M | -1.19M | -427.00K | 0.00 | 0.00 | -2.16M | 0.00 | 9.17M | 674.00K | 676.00K | -510.00K | -2.05M | 39.24M | 0.00 | -1.00K | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| Operating Expenses | 233.13M | 334.83M | 437.64M | 502.27M | 358.02M | 282.90M | 181.71M | 161.35M | 152.10M | 129.67M | 194.00M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.00M | 34.27M | 69.12M | 37.40M | 14.89M | 15.05M | 32.10M | 29.60M | 35.80M | 19.60M | 0.00 | 10.50M |
| Cost & Expenses | 374.50M | 461.54M | 558.97M | 633.72M | 454.03M | 337.44M | 226.66M | 195.71M | 179.98M | 150.16M | 205.91M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.11M | 46.19M | 99.25M | 58.85M | 20.11M | 18.03M | 35.80M | 32.40M | 39.80M | 24.50M | 0.00 | 13.60M |
| Interest Income | 11.86M | 2.82M | 1.22M | 4.90M | 8.50M | 1.07M | 429.00K | 234.00K | 132.00K | 96.00K | 343.00K | 544.00K | 231.00K | 53.00K | 780.00K | 9.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.00K | 15.00K | 129.00K | 2.61M | 6.63M | 7.80M | 9.77M | 18.44M | 20.05M | 18.48M | 34.18M | 18.09M | 1.00K | 19.00K | 8.23M | 2.14M | 6.46M | 0.00 | 1.80M | 0.00 | 0.00 | 29.46M | 0.00 | 0.00 | 0.00 | 24.40M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.97M | 3.09M | 2.86M | 2.05M | 862.56K | 667.87K | 715.59K | 777.59K | 812.00K | 844.00K | 892.00K | 449.00K | 76.00K | 63.00K | 582.00K | 251.00K | 386.00K | 795.00K | 810.00K | 754.00K | 671.00K | 8.29M | 21.22M | 2.42M | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| EBITDA | -50.90M | -100.65M | 14.28M | -12.71M | -15.06M | -106.63M | -44.82M | -56.53M | -97.41M | -39.78M | -134.62M | -152.32M | -66.79M | -249.90M | -55.16M | -19.87M | -38.44M | -31.16M | -19.29M | -9.85M | -6.09M | -25.45M | 16.14M | -224.00K | -4.81M | -7.90M | -5.60M | -17.10M | 5.60M | 18.70M | 1.70M |
| EBITDA Ratio | -16.59% | -24.45% | 4.31% | -2.39% | -3.69% | -47.36% | -24.49% | -50.82% | -120.42% | -170.16% | -681.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -437.07% | -6,280.80% | -3,358.80% | -3,309.93% | -732.53% | 6.42% | 29.96% | -2.85% | -27.11% | -8.95% | -15.64% | -87.44% | 16.15% | 100.00% | 9.52% |
| Operating Income | -67.59M | -92.34M | 22.28M | -19.66M | -24.28M | -108.23M | -45.56M | -65.63M | -98.22M | -95.96M | -182.11M | -116.75M | -44.16M | -45.10M | -52.30M | -28.18M | -40.73M | -31.16M | -18.91M | -11.09M | -38.82M | -32.66M | -5.08M | -2.56M | -6.81M | -16.80M | -8.10M | -18.30M | 4.60M | 18.70M | 1.10M |
| Operating Income Ratio | -22.02% | -25.01% | 3.82% | -3.20% | -5.65% | -47.22% | -25.15% | -50.45% | -120.14% | -177.03% | -691.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -553.06% | -6,232.20% | -3,781.60% | -1,090.66% | -527.10% | -49.86% | -9.44% | -14.59% | -60.71% | -88.42% | -33.33% | -85.12% | 15.81% | 100.00% | 7.48% |
| Total Other Income/Expenses | 13.92M | 2.06M | 789.00K | 2.40M | 1.80M | -8.12M | -9.26M | -10.76M | -20.07M | 36.75M | 12.69M | -54.20M | -22.73M | -204.92M | -29.36M | 7.22M | -7.08M | 3.64M | -2.35M | 222.00K | 12.24M | -883.00K | -298.00K | 525.00K | -1.63M | -5.50M | -3.20M | 1.60M | 900.00K | 0.00 | 200.00K |
| Income Before Tax | -53.67M | -103.81M | 11.29M | -17.26M | -22.48M | -116.35M | -54.82M | -76.38M | -118.29M | -59.20M | -169.42M | -170.07M | -66.61M | -250.09M | -59.76M | -20.70M | -39.03M | -27.72M | -19.41M | 11.35M | -26.58M | -33.55M | -4.71M | -2.22M | -10.15M | -30.10M | -11.30M | -16.70M | 5.50M | 0.00 | 1.30M |
| Income Before Tax Ratio | -17.49% | -28.12% | 1.94% | -2.81% | -5.23% | -50.76% | -30.27% | -58.72% | -144.69% | -109.22% | -642.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -529.99% | -5,543.80% | -3,881.00% | 1,115.54% | -360.90% | -51.21% | -8.76% | -12.66% | -90.48% | -158.42% | -46.50% | -77.67% | 18.90% | 0.00% | 8.84% |
| Income Tax Expense | 5.44M | 2.00M | 3.56M | 745.00K | 164.00K | 96.00K | 13.05M | 9.97M | -3.09M | -2.84M | -3.19M | 9.12M | 2.52M | -501.00K | -440.00K | -674.00K | -837.00K | -799.00K | -698.00K | 7.33M | -7.36M | 3.54M | 412.00K | 342.00K | -27.00K | 100.00K | 600.00K | -1.10M | 1.40M | 15.90M | 500.00K |
| Net Income | -59.11M | -105.80M | 7.73M | -18.00M | -22.65M | -116.45M | -67.87M | -86.35M | -115.20M | -56.36M | -166.23M | -179.18M | -69.13M | -249.59M | -59.32M | -20.02M | -38.20M | -26.92M | -18.71M | 4.01M | -19.22M | -37.08M | -4.76M | 2.36M | 4.37M | -28.80M | -7.70M | -15.60M | 4.10M | 2.80M | 900.00K |
| Net Income Ratio | -19.26% | -28.66% | 1.33% | -2.93% | -5.27% | -50.80% | -37.47% | -66.38% | -140.91% | -103.99% | -630.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -518.63% | -5,384.00% | -3,741.40% | 394.49% | -261.02% | -56.61% | -8.85% | 13.43% | 38.96% | -151.58% | -31.69% | -72.56% | 14.09% | 14.97% | 6.12% |
| EPS | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -1.03 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.67 | 6.42 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| EPS Diluted | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -0.99 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.40 | 3.02 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| Weighted Avg Shares Out | 407.66M | 401.16M | 395.99M | 381.76M | 342.54M | 297.24M | 270.65M | 210.61M | 179.59M | 173.72M | 161.02M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 7.12M | 149.89K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
| Weighted Avg Shares Out (Dil) | 407.66M | 401.16M | 402.48M | 381.76M | 342.54M | 297.24M | 270.65M | 211.87M | 180.65M | 173.82M | 167.07M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 12.04M | 842.09K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second...
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in...
LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok
LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin LA BOUTIQUE, the leading Thai fashion designer brand celebrated...
Amarin Board of Directors Announces CEO Transition
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT 1 -- --...
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd...
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
Amarin Reports First Quarter 2024 Business Update and Financial Results
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK--
Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in...
Source: https://incomestatements.info
Category: Stock Reports